Key result
VCAM-1-targeted shRNA-Smad3 lipopolyplexes reduce valvular endothelial-to-mesenchymal transition in a murine model.
Why the study?
Endothelial to mesenchymal transition of valvular endothelial cells driven by Smad3 promotes calcific aortic valve disease, and whether silencing Smad3 via targeted nanoparticles could hinder this process is unknown.
Does V-LPP/shSmad3 reduce endothelial-to-mesenchymal transition in human valvular endothelial cells and a murine model of atherosclerosis with diabetes?
Does V-LPP/shSmad3 reduce endothelial-to-mesenchymal transition in human valvular endothelial cells and a murine model of atherosclerosis with diabetes?
VCAM-1-targeted nanocarriers delivering shRNA-Smad3 effectively reduce endothelial-to-mesenchymal transition in valvular endothelial cells, suggesting a potential novel therapeutic approach for calcific aortic valve disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in aortic valve disease; leaves open targeted Smad3 silencing for future human studies.
Endothelial to mesenchymal transition (EndMT) of valvular endothelial cells (VEC) is a key process in the development and progression of calcific aortic valve disease (CAVD). High expression of the Smad3 transcription factor is crucial in the transition process. We hypothesize that silencing Smad3 could hinder EndMT and provide a novel treatment for CAVD. We aimed at developing nanoparticles encapsulating short-hairpin (sh)RNA sequences specific for Smad3 targeted to the aortic valve. We synthesized VCAM-1-targeted lipopolyplexes encapsulating shRNA-Smad3 plasmid (V-LPP/shSmad3) and investigated their potential to reduce the EndMT of human VEC. VEC incubation in a medium containing high glucose concentrations and osteogenic factors (HGOM) triggers EndMT and increased expression of Smad3. Exposed to lipopolyplexes, VEC took up efficiently the V-LPP/shSmad3. The latter reduced the EndMT process in VEC exposed to HGOM by downregulating the expression of αSMA and S100A4 mesenchymal markers and increasing the expression of the CD31 endothelial marker. In vivo, V-LPP/shSmad3 accumulated in the aortic root and aorta of a murine model of atherosclerosis complicated with diabetes, without affecting the liver and kidney function. The results suggest that targeting activated VEC with lipopolyplexes to silence Smad3 could be an effective, novel treatment for CAVD mediated by the EndMT process.
No takes yet. Share an insight, caveat, or question.
Voicu et al. (2024) studied Calcific aortic valve disease. VCAM-1-targeted lipopolyplexes encapsulating shRNA-Smad3 plasmid (V-LPP/shSmad3) was evaluated on Endothelial to mesenchymal transition (EndMT) reduction. VCAM-1-targeted lipopolyplexes encapsulating shRNA-Smad3 reduced endothelial-to-mesenchymal transition in valvular endothelial cells and accumulated in the aortic root of a murine model.
Synapse has enriched 10 related papers. Consider them for comparative context: